ArticleBlood2020
Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL.
Registry-linked trialOpen access · bronzeAbstract readLetter
In one paragraph
Article in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06175702 (Treatment Protocol for Newky Diagnosed Adult Ph-Chromosome Positive), which is not on this map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment Protocol for Newky Diagnosed Adult Ph-Chromosome Positive (BCR::ABL1) Acute Lymphoblastic Leukemia (LALPh2022)
Who cites it
36 citing papers in PubMed, 68 citations in OpenAlex.
- Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL.Blood advances · 2026Article
- Olverembatinib: A New Treatment for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.Cancers · 2026Review
- Current and emerging maintenance strategies after stem cell transplantation in children and adolescents with acute leukemias.Molecular therapy. Oncology · 2026Review
- A critical review of management of allogeneic transplant-eligible adults with Ph+ acute lymphoblastic leukaemia.British journal of haematology · 2026Review
- Toward a chemotherapy and allo-HSCT free future: the evolution of treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia.Frontiers in immunology · 2026Review
- Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approaches.Hematology. American Society of Hematology. Education Program · 2025Review
- Comparison of clinical outcomes between preemptive and maintenance therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.International journal of hematology · 2025Article
- Improved outcomes over time in patients aged ≥60 years undergoing allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in first complete remission: a large study by the EBMT acute leukemia working party.Bone marrow transplantation · 2025Article
- The Role of Transplant for Philadelphia-positive B-cell Acute Lymphoblastic Leukemia in 2025.Current oncology reports · 2025Review
- Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Post-transplant TKIs for Ph+ ALL: practices to date and clinical significance.International journal of hematology · 2025Article
- Tyrosine Kinase Inhibitor Post-Allogeneic Stem Cell Transplantation in Adult Philadelphia-Positive B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions.Current issues in molecular biology · 2025Review
- Dasatinib maintenance following allogeneic transplantation in acute myeloid leukemia with KIT mutation.Bone marrow transplantation · 2025Article
- Editorial: Allogenic hematopoietic cell transplant in hematological malignancies: controversies and perspective.Frontiers in oncology · 2025Article
- Efficacy and safety of olverembatinib as maintenance therapy after allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.Annals of hematology · 2025Article
- Review
- Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions.Leukemia · 2024Review
- Article
- Article
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
19 authors at 1 institution in 1 country.
Neeraj SainiDepartment of Stem Cell Transplantation and Cellular Therapy and.
David MarinDepartment of Stem Cell Transplantation and Cellular Therapy and.
Celina LedesmaDepartment of Stem Cell Transplantation and Cellular Therapy and.
Ruby DelgadoDepartment of Stem Cell Transplantation and Cellular Therapy and.
Gabriela RondonDepartment of Stem Cell Transplantation and Cellular Therapy and.
Uday R PopatDepartment of Stem Cell Transplantation and Cellular Therapy and.
Qaiser BashirDepartment of Stem Cell Transplantation and Cellular Therapy and.
Chitra M HosingDepartment of Stem Cell Transplantation and Cellular Therapy and.
Yago NietoDepartment of Stem Cell Transplantation and Cellular Therapy and.
Amin M AlousiDepartment of Stem Cell Transplantation and Cellular Therapy and.
Muzaffar H QazilbashDepartment of Stem Cell Transplantation and Cellular Therapy and.
Stefan CiureaDepartment of Stem Cell Transplantation and Cellular Therapy and.
Elizabeth ShpallDepartment of Stem Cell Transplantation and Cellular Therapy and.
Issa KhouriDepartment of Stem Cell Transplantation and Cellular Therapy and.
Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Richard E ChamplinDepartment of Stem Cell Transplantation and Cellular Therapy and.
Partow KebriaeiDepartment of Stem Cell Transplantation and Cellular Therapy and.
The University of Texas MD Anderson Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MNCI NIH HHS P30 CA016672
Abstract
PubMed holds no abstract for this paper.
Indexed as
Postoperative CareAntineoplastic AgentsCombined Modality TherapyHematopoietic Stem Cell TransplantationHumansPrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsTransplantation, HomologousTreatment OutcomeAntineoplastic AgentsProtein Kinase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT06175702ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.